1. Bataller, R. Liver fibrosis / R. Bataller, D.A. Brenner // J. Clin. Invest. - 2005. - Vol. 115. - P. 209-218.
2. A comparison of fibrosis progression in chronic liver diseases / T.A. Poynard [et al.] // J. Hepatol. - 2003. - Vol. 38. - P. 257-265.
3. Mormone, E. Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches / E. Mormone, J. George, N. Nieto // Chem. Biol. Interac. - 2011. - Vol. 193, N 3. - P. 225-231.
4. Liver cirrhosis mortality in Europe, with special attention to Central and Eastern Europe / W.A. Zatonsky [et al.] // Eur. Addict. Res. - 2010. - Vol. 16, N 4. - P. 193-201.
5. Смертность в Республике Беларусь за 2014-2015 гг. : офиц. стат. сб. за 2014-2015 гг. / Респ. науч.-практ. центр мед. технологий, информатизации, управления и экономики здравоохранения. - Минск : Респ. науч. мед. б-ка, 2016. - 208 с.
6. Ивашкин, В.Т. Лечение осложнений цирроза печени / В.Т. Ивашкин, М.В. Маевская. - М. : Литтерра, 2011. - 64 с.
7. Parsons, C.J. Molecular mechanisms of hepatic fibrogenesis / C.J. Parsons, M. Takashima, R.A. Rippe // J. Gastroenterol. Hepatol. - 2007. - Vol. 22, iss. 1. - P. 79-84.
8. Lemos, Q.T. Angiogenesis and experimental hepatic fibrosis / Q.T. Lemos, Z.A. Andrade // Mem. Inst. Oswaldo Cruz. - 2010. - Vol. 105, iss. 5. - P. 611-614.
9. Tsochatzis, E.A. Liver cirrhosis / E.A. Tsochatzis, J. Bosch, A.K. Burroughs // Lancet. - 2014. - Vol. 383. - P. 1749- 1761.
10. Bonis, P.A. Is liver fibrosis reversible? / P.A. Bonis, S.L. Friedman, M.M. Kaplan // N. Engl. J. Med. - 2001. - Vol. 344. - P. 452-454.
11. Liaw, Y.F. Reversal of cirrhosis: an achievable goal of hepatitis B antiviral therapy / Y.F. Liaw // J. Hepatol. - 2013. - Vol. 59. - P. 880-881.
12. Ellis, E.L. Clinical evidence for the regression of liver fibrosis / E.L. Ellis, D.A. Mann // J. Hepatol. - 2012. - Vol. 56, N5. - P. 1171-1180.
13. Kang, Q. Curcumin suppresses expression of low-density lipoprotein (LDL) receptor, leading to the ingibition of LDL-induced activation of hepatic stellate cells / Q. Kang, A. Chen // Br. J. Pharmacol. - 2009. - Vol. 157, iss. 8. - P. 1354- 1367.
14. Hirschfield, G.M. Progress in the genetics of primary biliary cirrhosis / G.M. Hirschfield, P. Invernizzi // Semin. Liver Dis. - 2011. - Vol. 31, iss. 2. - P. 147-156.
15. Risk factors and prediction of long-term outcome in primary biliary cirrhosis / H. Ishibashi [et al.] // Intern. Med. - 2011. - Vol. 50, iss. 1. - P. 1-10.
16. Эффективность урсодезоксихолевой кислоты в лечении больных холестатической формой алкогольной болезни печени и первичным билиарным циррозом / Е.Н. Широкова [и др.] // РЖГГК. - 2007. - №3. - С. 52-58.
17. High dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis / D.M. Harnois [et al.] // Am. J. Gastroenterol. - 2001. - Vol. 96. - P. 1558-1562.
18. Xiang, Z. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis / Z. Xiang, Y.P. Chen, K.F. Ma // BMC Gastroenterol. - 2013. - Vol. 13, N 1. - P. 140.
19. Sha, M. The efficacy of pentoxifylline in the treatment of vascular dementia / M. Sha, C. Callahan // Alzheimer Dis. Assoc. Disord. - 2003. - Vol. 17, iss. 1. - P. 46-54.
20. Хронические цереброваскулярные расстройства - современные подходы к лечению / П.Р. Камчатнов [и др.] // Рус. мед. журн. - 2008. - Т. 16, №6. - С. 358-361.
21. Pentoxifylline in the treatment of radiation-induced fibrosis / P. Ocunieff [et al.] // J. Clin. Oncol. - 2004. - Vol. 22, iss. 11. - P. 2207-2213.
22. O’Shea, R.S. Alcoholic liver desease / R.S. O’Shea, S. Dasarathy, A.J. McCullough / J. Hepatol. - 2010. - Vol. 51, N 1. - P. 307-328.
23. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis / S.K. Satapathy [et al.] // Am. J. of Gastroenterol. - 2004. - Vol. 99, iss. 10. - P. 1946-1952.
24. Rokey, D.C. Antifibrotic therapy in chronic liver desease / D.C. Rokey // Clin. Gastroenterol. Hepatol. - 2005. - Vol. 3, N2. - P. 95-107.
25. Автандилов, Г.Г. Введение в количественную патологическую морфологию / Г.Г. Автандилов. - М. : Медицина, 1980. - 216 с.
26. An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis / J.J. Cho [et al.] // J. Gastroenterol. - 2000. - Vol. 118, N 6. - P. 1169-1178.
27. Protective effects of norursodeoxycholic acid versus ursodeoxycholic acid on thioacetamide-induced rat liver fibrosis / V.U. Buko [et al.] // J. Clin. Exp. Hepatol. - 2014. - Vol. 4, N 4. - P. 293-301.
28. Ursodeoxycholic acid treatment improves hepatocyte ultrastructure in rat liver fibrosis / N. Mas [et al.] // World J. Gastroenterol. - 2008. - Vol. 14, N 7. - P. 1108-1111.
29. Resolution of thioacetamide induced liver fibrosis in rats treated with pentoxifylline / V.U. Buko [et al.] // J. Hepatol. - 2007. - Vol. 46, suppl. 1. - S80.
30. Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary billiary fibrosis // C. Raetsch [et al.] // Gut. - 2002. - Vol. 50, N 2. - P. 241-247.